周一“星”视角|SBRT与CRT治疗无法手术的Ⅰ期NSCLC:3期随机临床试验;评估ChatGPT作为肺癌手术常见问题的患者资源

学术   科学   2024-10-14 20:20   四川  



本期胸小星将为大家带来SBRT与CRT治疗无法手术的Ⅰ期NSCLC:3期随机临床试验;评估ChatGPT作为肺癌手术常见问题的患者资源,一起来看看吧!


2017·EATTS 

01

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial

Anand Swaminath1, Sameer Parpia2, Marcin Wierzbicki3, Vijayananda Kundapur4, Sergio Faria5, Gordon S Okawara1, Theodoros K Tsakiridis1, Naseer Ahmed6, Alexis Bujold7, Khalid Hirmiz8, Timothy Owen9, Nelson Leong10, Kevin Ramchandar11, Edith Filion12, Harold Lau13, Zsolt Gabos14, Robert Thompson15, Brian Yaremko16, Selma Mehiri17, Alexander V Louie18, Kimmen Quan1, Mark N Levine2, James R Wright1, Timothy J Whelan1

1 Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada.

2 Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

3 Juravinski Cancer Centre, Department of Medical Physics, McMaster University, Hamilton, Ontario, Canada.

4 Saskatchewan Cancer Agency, Department of Radiation Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

5 Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.

6 Section of Radiation Oncology, Department of Radiology, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.

7 Département de Radio-oncologie Clinique-Enseignement-Recherche, Centre intégré universitaire de soins et services sociaux de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.

8 Department of Radiation Oncology, Windsor Regional Cancer Centre, Windsor, Ontario, Canada.

9 Department of Oncology, Queen's University, Cancer Centre of Southeast Ontario at Kingston Health Sciences Centre, Kingston, Ontario, Canada.

10 Allan Blair Cancer Centre, Department of Radiation Oncology, University of Saskatchewan, Regina, Saskatchewan, Canada.

11 Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.

12 Radiation Oncology Department, Centre Hospitalier de l'Université de Montréal, Notre Dame Hospital, Montreal, Quebec, Canada.

13 Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

14 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

15 Department of Radiation Oncology, Dalhousie University, Saint John, New Brunswick, Canada.

16 Department of Radiation Oncology, Western University, London, Ontario, Canada.

17 Département de Radio-oncologie, CISSS Montérégie, Hôpital Charles Lemoyne, Montreal, Quebec, Canada.

18 Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.


Objective: 

To examine whether stereotactic body radiotherapy (SBRT) would improve local control (LC) compared with hypofractionated conventional radiotherapy (CRT).


Methods: 

This phase 3 randomized clinical trial (RCT) was conducted in 16 Canadian centers. Patients with medically inoperable stage I (≤5 cm) NSCLC were randomized 2:1 to SBRT of 48 Gy in 4 fractions (peripheral NSCLC) or 60 Gy in 8 fractions (central NSCLC) vs CRT of 60 Gy in 15 fractions. Data were collected from May 2014 to January 2020, and data were analyzed from July 2022 to July 2023. The primary objective was to determine the effectiveness of SBRT compared with CRT based on LC at 3 years. Secondary outcomes included event-free survival, overall survival, and toxic effects. All radiation plans were subject to real-time/final review. Local failures were centrally adjudicated. The study was designed to detect a 3-year LC improvement of SBRT from 75% to 87.5%. The target sample size was 324 patients.


Results: 

Of 233 included patients, 119 (51.1%) were male, and the mean (SD) age was 75.4 (7.7) years; the median (IQR) follow-up was 36.1 (26.4-52.8) months. A total of 154 patients received SBRT and 79 received CRT. The 3-year LC was 87.6% (95% CI, 81.9%-93.4%) for SBRT and 81.2% (95% CI, 71.9%-90.5%) for CRT (hazard ratio [HR], 0.61; 95% CI, 0.31-1.20; = 0.15). The HR was 1.02 (95% CI, 0.72-1.45; = 0.87) for event-free survival and 1.18 (95% CI, 0.80-1.76; = 0.40) for overall survival. Minimal acute toxic effects were observed. Among those randomized to SBRT, late grade 3 or 4 toxic effects occurred in 5 of 45 (11%) with central NSCLC and 2 of 109 (1.8%) with peripheral NSCLC; among those randomized to CRT, in 1 of 19 (5%) with central NSCLC and 1 of 60 (2%) with peripheral NSCLC. One patient who received SBRT for an ultracentral lesion (target overlapping proximal bronchus) experienced a possible treatment-related grade 5 event (hemoptysis).


Conclusion: 

This RCT compared lung SBRT with hypofractionated CRT that included central/ultracentral tumors. No difference was detected in LC between groups. Severe toxic effects were limited, including patients with central tumors. The trial provides important prospective data evaluating SBRT; however, further research is necessary to determine if SBRT is more effective than CRT for peripheral and central NSCLC.


[CITATION]: Swaminath A, Parpia S, Wierzbicki M, et al. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Sep 19:e243089.

[DOI]: 10.1001/jamaoncol.2024.3089

[IF]: 22.5

向下滑动查看所有内容 


立体定向放疗与低分割放疗治疗无法手术的Ⅰ期非小细胞肺癌:LUSTRE 3期随机临床试验

胸“星”外科学术团队成员 李佳泽 

目的

探究立体定向放射治疗(stereotactic body radiotherapy, SBRT)与低分割常规放射治疗(conventional radiotherapy, CRT)相比,能否改善局部控制情况(local control, LC)。

方法

本项3期随机对照试验(randomized clinical trials, RCT)在加拿大的16个中心开展。无法手术的期(5 cmNSCLC患者按21的比例随机分配,分别接受4次总剂量48Gy(外周型NSCLC)或8次总剂量60Gy(中NSCLC)的SBRT15次总剂量60GyCRT本试验20145月至20201月收集数据,在20227月至20237月分析数据主要目的是根据3LC确定SBRTCRT相比的有效性。次要结局包括无事件生存期、总生存期和毒性反应。所有的辐射计划都经过实时/最终审查。单个中心的失误已被集中裁定。本研究旨在检测出75%87.5%3LC提升。目标样本量为324名患者。

结果

在纳入的233名患者中,119名(51.1%)为男性,平均(标准差)年龄为75.4(7.7)岁;中位(四分位距)随访时间为36.1(26.4-52.8)个月。共有154名患者接受了SBRT,79名患者接受了CRT。SBRT组的3年LC为87.6%(95% CI, 81.9%-93.4%),CRT组则为81.2%(95% CI, 71.9%-90.5%)(风险比 [hazard ratio, HR], 0.61; 95% CI, 0.31-1.20; P = 0.15)。无事件生存期的HR为1.02(95% CI, 0.72-1.45; = 0.87),总生存期的HR为1.18(95% CI, 0.80-1.76; = 0.40)。仅观察到轻微的急性毒性反应。随机分配接受SBRT的患者中,45名中央型NSCLC患者中有5名(11%),109名外周型NSCLC患者中有2名(1.8%);随机分配接受CRT的患者中,19名中央型NSCLC患者中有1名(5%),60名外周型NSCLC患者中有1名(2%)出现了晚期3或4级毒性反应。一名接受了SBRT的患者因超中央型病变(靶区与近端支气管重叠)经历了一例可能与治疗相关的5级事件(咳血)。

结论

本项RCT比较了包括中央型/超中央型肿瘤在内的肺部SBRT与低分割CRT。组间LC没有检测到差异。包括中央型肿瘤患者在内,严重毒性反应有限。本项试验提供了评估SBRT重要的前瞻性数据;然而,还需要进一步的研究来确定外周型和中央型的NSCLC中SBRT是否比CRT更有效。

Figure 2. Kaplan-Meier Curves for Outcomes

Table. Worst Toxic Effects By Grade and Tumor Location

2017·EATTS 

02

Evaluating ChatGPT as a Patient Resource for Frequently Asked Questions about Lung Cancer Surgery - A Pilot Study

Dana Ferrari-Light1, Robert E Merritt1, Desmond D'Souza1, Mark K Ferguson2, Sebron Harrison3, Maria Lucia Madariaga2, Benjamin E Lee3, Susan D Moffatt-Bruce4, Peter J Kneuertz1

1 Division of Thoracic Surgery, The Ohio State Wexner Medical Center, Columbus OH.

2 Section of Thoracic Surgery, Department of Surgery, The University of Chicago, Chicago IL.

3 Department of Cardiothoracic Surgery, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY.

4 Beth Israel Lahey Health, Burlington MA.

Objective: 

Chat-based artificial intelligence (AI) programs like ChatGPT are re-imagining how patients seek information. This study aims to evaluate the quality and accuracy of ChatGPT-generated answers to common patient questions about lung cancer surgery.


Methods:

A 30-question survey of patient questions about lung cancer surgery was posed to ChatGPT in July 2023. The ChatGPT-generated responses were presented to nine thoracic surgeons at four academic institutions who rated the quality of the answer on a 5-point Likert scale. They also evaluated if the response contained any inaccuracies and were prompted to submit free text comments. Responses were analyzed in aggregate.


Results:

For ChatGPT-generated answers, the average quality ranged from 3.1-4.2 out of 5.0, indicating they were generally "good" or "very good". No answer received a unanimous 1-star (poor quality) or 5-star (excellent quality) score. Minor inaccuracies were found by at least one surgeon in 100% of the answers, and major inaccuracies were found in 36.6%. Regarding ChatGPT, 66.7% of surgeons felt it was an accurate source of information for patients. However, only 55.6% felt they were comparable to answers given by experienced thoracic surgeons, and only 44.4% would recommend it to their patients. Common criticisms of ChatGPT-generated answers included lengthiness, lack of specificity regarding surgical care, and lack of references.


Conclusions:

Chat-based AI programs have potential to become a useful information tool for lung cancer surgery patients. However, the quality and accuracy of ChatGPT-generated answers need improvement before thoracic surgeons could consider this method as a primary education source for patients.


[CITATION]: Ferrari-Light D, Merritt RE, D'Souza D, et al. Evaluating ChatGPT as a Patient Resource for Frequently Asked Questions about Lung Cancer Surgery - A Pilot Study. J Thorac Cardiovasc Surg. 2024 Sep 24:S0022-5223(24)00837-7.

[DOI]: 10.1016/j.jtcvs.2024.09.030.

[IF]: 4.9

向下滑动查看所有内容


评估ChatGPT作为肺癌手术常见问题的患者资源—一项试点研究

胸“星”外科学术团队成员 孙可蒙 译


目的

类似ChatGPT这种基于聊天的人工智能(artificial intelligence, AI)程序正在重新定义患者获取信息的方式。本研究旨在评估ChatGPT生成的关于肺癌手术患者常见问题的回答的质量和准确性。

方法

2023年7月,向ChatGPT提出关于肺癌手术的30个患者问题。由四所学术机构的九位胸外科医生使用5点李克特量表对ChatGPT生成的回答进行了质量评分,还评估了回答中是否包含任何不准确之处,并被要求提交自由文本评论。所有回答都进行了汇总分析。

结果

ChatGPT生成回答的平均质量评分介于3.1-4.2分(满分5分),表明回答通常为“良好”或“非常好”。无回答获得全体一致的1星(质量差)或5星(质量优异)的评分。至少有一位外科医生在所有回答中发现了轻微不准确之处,在36.6%的回答中发现了重大不准确之处。66.7%的外科医生认为ChatGPT是患者信息的可靠来源。然而,只有55.6%的外科医生认为其回答可与经验丰富的胸外科医生提供的答案相当,且只有44.4%的外科医生会将ChatGPT推荐给患者。对ChatGPT生成回答的常见批评包括回答过长、缺乏对外科护理的具体描述以及缺乏参考资料。

结论

基于聊天的AI程序有潜力成为肺癌手术患者的有用信息工具。然而,在胸外科医生考虑将其作为患者的主要信息来源之前,ChatGPT生成回答的质量和准确性仍需要进一步改进。

Table 2. Thoracic surgeon free text comments on additional questions meant to summarize their opinion on ChatGPT-generated answers to common patient questions regarding lung cancer surgery.


Figure 1. Average quality rating for ChatGPT-generated answers to common patient questions regarding lung cancer surgery, grouped by question subject.

2017·EATTS 



胸外学术时间
胸外学术时间系胸“星”外科学术团队(EATTS)下特色平台,主要共享胸外科领域最前沿的医学论文及科普。此外还分享医学论文写作的基本技能,旨在为医学专业人士(尤其是胸外专业)或大众提供网络共享平台,让大家一起 EAT 每份胸外盛宴。
 最新文章